| Literature DB >> 33616892 |
Lei Tan1, Jun Yao2, Yadi Yang1, Wei Luo3, Xiaomin Yuan1, Lingchen Yang4, Aibing Wang5,6.
Abstract
Pseudorabies (PR), also called Aujeszky's disease, is a highly infectious disease caused by pseudorabies virus (PRV). Without specific host tropism, PRV can infect a wide variety of mammals, including pig, sheep, cattle, etc., thereby causing severe clinical symptoms and acute death. PRV was firstly reported in China in 1950s, while outbreaks of emerging PRV variants have been documented in partial regions since 2011, leading to significant economic losses in swine industry. Although scientists have been devoting to the design of diagnostic approaches and the development of vaccines during the past years, PR remains a vital infectious disease widely prevalent in Chinese pig industry. Especially, its potential threat to human health has also attracted the worldwide attention. In this review, we will provide a summary of current understanding of PRV in China, mainly focusing on PRV history, the existing diagnosis methods, PRV prevalence in pig population and other susceptible mammals, molecular characteristics, and the available vaccines against its infection. Additionally, promising agents including traditional Chinese herbal medicines and novel inhibitors that may be employed to treat this viral infection, are also discussed.Entities:
Keywords: Diagnosis methods; Multiple-species infection; Prevalence; Prevention and control measures; Pseudorabies virus (PRV)
Year: 2021 PMID: 33616892 PMCID: PMC7897889 DOI: 10.1007/s12250-020-00340-0
Source DB: PubMed Journal: Virol Sin ISSN: 1995-820X Impact factor: 4.327
Various diagnostic approaches developed in China.
| Target | Methods | Sensitivity and specificity | Reference |
|---|---|---|---|
| PRV antibody | Blocking ELISA: targeting to the gB antibody | High sensitivity (80.9%) and specificity (96.4%) compared with the commercial ELISA kit (IDEXX) | Sun HF |
Indirect ELISA: targeting to the gE antibody | Total 89.1% positive coincidence rate compared with the commercial ELISA kit (IDEXX) (allowing DIVA) | Zheng | |
Indirect ELISA: targeting to the gE antibody | High 88.0% sensitivity and 91.5% specificity compared with the commercial ELISA kit (IDEXX) (allowing DIVA) | Kou | |
Indirect ELISA: targeting to the gB antibody | Highly total positive coincidence rate (97.8%) compared with the commercial ELISA kit. and the lowest detection limit was 1: 128 dilution of the positive serum | Liu MM | |
ICA: targeting to the gE antibody | The lowest detection limit was 1:1280 dilution of the positive serum, and 95.3% positive coincidence rate compared with the commercial ELISA kit (IDEXX) (allowing DIVA) | Lei and Zhang ( | |
DFM: 2 targeting to the gE antibody | Total 74.7% positive coincidence rate compared with the conventional PCR, while which was more sensitive than the later one (allowing DIVA) | Xu LH | |
Liquid chip technology: targeting to the gE antibody | This method could be applied to detect both PRV and PRRSV antibodies with higher sensitivity than the commercial ELISA kits (allowing DIVA) | Xiao | |
IFAT: targeting to the gE antibody | High sensitivity (93.8%) and specificity (91.7%) compared with the commercial ELISA kit (IDEXX) (allowing DIVA) | Zhu | |
| PRV antigen | LFA: targeting to the gB antigen | Detection limit of inactivated PRV antigens were lower than 1 × 106.6 TCID50/0.1 mL with 86.7% positive coincidence rate compared with the conventional PCR | Wang TH |
| PRV DNA | NanoPCR: targeting to the | This test could be used for the differentiation of wild PRV and gene-deleted vaccine strains with higher sensitivity than the conventional PCR (allowing DIVA) | Ma |
DdPCR: targeting to the | Higher sensitivity (6.1 copies/μL) than qPCR with high specify (96.2%) compared with viral isolation (allowing DIVA) | Chen | |
LAMP: targeting to the | Showed 100 times higher sensitivity than conventional PCR with the detection limit of 1 fg/μL | Xu ZL | |
PCR combined with nucleic acid probe spot hybridization: targeting to the | The sensitivity was 100 times higher than conventional PCR, being 10 pg/μL and 1 ng/ul, respectively (allowing DIVA) | Wunaerhan | |
PCR: targeting to the | This approach could be used to distinguish between PRV wild virus, SA215 and Bartha-K61 vaccine strains with detection limit of 1.8 × 106 copies/μL (allowing DIVA) | Jiang | |
RPA: targeting to the | Both the sensitivities of | Liu LB | |
TaqMan qPCR: targeting to the | The detection limits of | Lan | |
QPCR: targeting to the | The detection limit was lower than 1000 copies/μL, showing higher sensitivity than conventional PCR | Hua | |
QPCR: targeting to the | The detection limit was 10 copies/μl with high specificity (100%) compared with conventional PCR and commercial kits | Wen | |
Multiple RT-PCR: targeting to the | The approach could detect the nucleic acids of PRV, PCV2, PPV, PPRSV, JEV, and CSFV with the detection limit pf 10–3 ng/μL for PRV (allowing DIVA) | Li | |
QIAxcel CGE: targeting to the | This method could be applied for the detection of PRV, CSFV, JEV, PCV2, PRRSV, PPV and ASFV, with the detection limit of 4.53 × 103 copies/μL for PRV (allowing DIVA) | Wu | |
Multiple PCR: targeting to the | This method could be applied for the detection of PRV, PCV2 and PPV, with the detection limit of 72 pg/μL for PRV (allowing DIVA) | Xin | |
| NGS | This approach could be used for detecting undetermined pathogens with high sensitivity | Ai |
DIVA: Distinction between the infected and vaccinated animals; ICA: Gold immunochromatographic assay; DFM: Direct immunofluorescence method; IFAT: Indirect immunofluorescent antibody detection method; LFA: Lateral flow assay; NanoPCR: Nanoparticle-assisted PCR assay; DdPCR: Droplet digital PCR assay; LAMP: Loop-mediated isothermal amplification; RPA: Recombinase polymerase amplification; QIAxcel CGE: QIAxcel capillary gel electrophoresis; NGS: Next generation sequencing.
Fig. 1Current sero-prevalence of pseudorabies virus in pigs. Results of 108 representative studies investigating PRV sero-prevalence in pigs across distinct regions covering 29 provinces of China. These data collected from Chinese and English databases from 2011 to the present were analyzed. Data of the regions marked with white were not available.
Clinical signs and pathological characteristics of different PRV-infected species in China.
| Species | Case numbers | Clinical signs | Pathological characteristics | Reference |
|---|---|---|---|---|
| Cattle/cow | 9 | Pruritus, nervous symptoms, being excited and manic, etc | Leptomeningeal hyperemia, consolidation of lung lobes, etc | Cheng |
| Dog | 12 | Pruritus, hypersalivation, broken winded, etc | Endocardial and thymic hemorrhage, pulmonary hemorrhage and/or congestion, etc | Zhang L |
| Wolf | 1 | Pruritus, vomiting, quadriplegia, etc | hemorrhagic spots and edema in the meninges Hemorrhagic spots and necrosis in the liver, etc | Lian |
| Goat/sheep | 11 | Pruritus, nervous symptoms, muscle spasm, etc | Leptomeningeal hyperemia, consolidation of lung lobes, etc | Zhang |
| Fox | 2 | Pruritus, vomiting, broken winded, etc | Sugillation in the lung, hemorrhage in the spleen, thymus and liver, etc | Jin |
| Mink | 9 | Pruritus, diarrhea, muscle spasm, etc | Hemorrhage in the thymus and submandibular lymph node, liver and spleen tumefaction, etc | Liu |
| Raccoon | 3 | Pruritus, vomiting, etc | Not mentioned | Liu |
Human PRV infection cases in China.
| Date | Age/Sex | Occupation | Injured at work | Interval after injury | Symptoms | Diagnostic methods | Treatment | Reference |
|---|---|---|---|---|---|---|---|---|
| NA | 43/male | Veterinarian | Yes | 4 days | Fever, headache, tonic–clonic seizures and coma, etc | NGS; PCR and ELISA methods | Acyclovir treatment for 2 weeks; antibiotics | Yang H |
| NA | 59/male | Swineherd | Yes | 6 days | Fever, seizures, tonic–clonic seizures and coma, etc | NGS, ELISA method | Antimicrobial therapy, penciclovir and foscarnet sodium treatment for 17 days | Zheng |
| NA | 44/male | Sick pig handler | NA | NA | Fever, seizures, visual loss, etc | NGS and PCR methods | Acyclovir and other treatments | Wang Y |
| 2011 | A young female | NA | NA | Least 5 days | Fever, chotic behavior, recurrent seizures, etc | NGS (CSF) | Acyclovir, foscarnet, VPA treatment, etc. (death) | Fan |
| Nov 2016 | 42/female | Pork cutter/cooker | NA | 4 days | Fever, tonic–clonic seizures, coma, blindness, etc | NA | Acyclovir and other treatments | Zhao |
| Jun 2017 | 46/female | Swineherd | Exposed to the sewage | 3 days | Fever, visual impairment, headaches, etc | NGS, real-time PCR and PCR methods | NA | Ai |
| Dec 2017 | 55/male | Pork cutter/cooker | NA | 4 days | Fever, headaches, cough, coma, etc | NGS (CSF) | NA | Zhao |
| Dec 2017 | 51/man | Pork cutter/cooker | NA | NA | Fever, headache, coma, tonic–clonic seizures and death, etc | NGS (CSF) | Acyclovir and other treatments | Zhao |
| Nov 2017 | 38/male | Pork cutter/cooker | NA | 4 days | Fever, headache, coma, tonic–clonic seizures, etc | NA | Acyclovir and other treatments | Zhao |
| 2018 | A mid-aged male | NA | NA | NA | Fever, bilateral retinal necrosis, consciousness loss, etc | NGS (CSF) | Acyclovir treatment (death) | Fan |
| 2018 | A mid-aged male | Pig farmer | NA | One month | Fever, cognitive decline, consciousness loss, etc | NGS (CSF) | Acyclovir, foscarnet, and methylprednisolone treatment, etc | Fan |
| 2018 | A young male | NA | NA | Least 3 days | Fever, seizures, consciousness loss, etc | NGS (CSF) | Continues renal replacement, clonazepam, VPA, acyclovir, etc | Fan |
| Before Mar 2018 | 59/male | Pig farmer | Yes | 40 days | Fever, weakness, tonic–clonic seizures, respiratory failure, etc | NGS (CSF) | Penciclovir treatment combined with Sodium phosphonate | Fan |
| Feb 2018 | 50/male | Pig slaughterer | Yes | 5 days | Fever, headache, visual disturbance, coma, etc | NGS | IVIG treatment for 5 days, Glucocorticoids, antiviral and other treatments | Yang X |
| Mar 2018 | 50/female | Pork cutter | Yes | 7 days | Fever, coma, respiratory failure, seizure, etc | NGS | Yang X | |
| Mar 2018 | 43/male | Sick pig handler | Yes | 7 days | Fever, extremity tremors, respiratory failure, etc | NGS | Yang X | |
| Apr 2018 | 59/male | Pork cutter | Yes | 10 days | Fever, seizures, respiratory failure, etc | NGS | Yang X | |
| Apr 2018 | 50/male | Pork cutter | NA | NA | Fever, seizure, respiratory failure, etc | NGS | Yang X | |
| Apr 2018 | 25/male | Veterinarian | Exposed to the PRV infected pigs | 6 days | Fever, headache, cognitive impairment, seizures, consciousness loss, and meningeal irritation sign | NGS (CSF), DdPCR, etc | Ganciclovir and foscarnet treatment | Liu Q |
| Aug 2018 | 43/male | Veterinarian | Exposed to the diseased pigs | 11 days | Fever, respiratory failure, headache, cognitive impairment, seizures, consciousness loss, and meningeal irritation sign | Virus isolation, NGS (CSF), ddPCR, etc | Acyclovir treatment | Liu Q |
| Mar 2019 | 44/male | Pork cutter | Yes | 14 days | Fever, seizure, tonic–clonic seizures and coma, etc | NGS and PCR methods | Acyclovir, dexamethasone and other treatments | Wang |
| Mar 2019 | 35/male | Pig butcher | Exposed to the pigs and pork | 7 days | Fever, respiratory failure, headache, cognitive impairment, seizures, and consciousness loss | NGS (CSF), ddPCR, etc | Acyclovir and foscarnet treatment | Liu Q |
| Feb 2019 | 49/male | Pig butcher | Exposed to the pork | 3 days | Fever, respiratory failure, headache, cognitive impairment, seizures, and consciousness loss | NGS (CSF), ddPCR, etc | Ganciclovir and foscarnet treatment | Liu Q |
NA: no available; NGS: next generation sequencing; CSF: cerebral spinal fluid; DdPCR: droplet digital PCR.
Fig. 2Phylogenetic trees based on the different gene sequences, showing the genetic relationships among PRV strains from different hosts/regions, were constructed by the neighbor-joining method with a bootstrap test of 1000 replicates using MEGA 7.0 software. The hosts, countries, years, and GenBank accession numbers of the reference strains employed in this phylogenetic tree are labeled, Black and red diamonds represent isolates from human and vaccines generated.
Fig. 3Alignment of partial amino acid sequence of gB (A), gC (B), and gD (C) genes of representative PRV strains (genotype I strains (eg. Bartha and Becker), classical (eg. Fa and Ea) and variant strains (JS-2012, hSD-1/2019, and HeN1) in the genotype II). Unique aa deletions/insertions existed between different PRV strains are shown in the green box.
List of genetic modified vaccines against PRV infection.
| Gene-deleted vaccines | Strain | Features | Technologies | Main advantages | Status | References |
|---|---|---|---|---|---|---|
| Single gene-deleted vaccine (inactivated) | AH02LA (variant) | BCA | High safe without virulence reversion; Allowing DIVA with more complete protection than Bartha K61 vaccines | Not available | Wang J | |
| HN1201 (variant) | HR | Licensed | Wang T | |||
| Double gene-deleted vaccine (inactivated) | ZJ01 (variant) | BCA | Not available | Gu | ||
| Single gene-deleted vaccine | TJ (variant) | HR | Safe to piglets without visible gross pathological lesions; Effective immune response; Completely provides protection against emerging PRV variants; Allowing DIVA; | Not available | Wang | |
| Double gene-deleted vaccine | Ea (classical) | NA | Licensed | He | ||
| JS-2012 (variant) | HR | Not available | Tong | |||
| XJ (variant) | Yin | |||||
| AH02LA (variant) | HR | Not available | Wang J | |||
| JS-2012 (variant) | High-temperature passage | Not available | Liang | |||
| Triple gene-deleted vaccine | Fa (classical) | HR | Safer than double gene-deleted vaccines to piglets and growing pigs; Effective immune response; Completely provides protection against emerging PRV variants; Allowing DIVA; | Licensed | Zhu | |
| SA215 (classical) | ||||||
| ZJ01 (variant) | Not available | Dong | ||||
| SMX (variant) | Not available | Hu RM | ||||
| HN1201 (variant) | Not available | Zhang C | ||||
| HeN1 (variant) | CRISPR/Cas9 | Not available | Tang | |||
| NY (variant) | Not available | Zhao | ||||
| 201,715 (variant) | CRISPR/Cas9 | Not available | Lin | |||
| Four gene-deleted vaccine | C (variant) | Natural losses | Licensed | Gao |
HR: homologous DNA recombination; DIVA: distinction between the infected and vaccinated animals; BCA: bacterial artificial chromosome; CRISPR/Cas9: clustered regularly interspaced short palindromic repeats/Cas9.
List of live attenuated recombinant vaccines against PRV infection.
| Insertion sites | Parental PRV strains | Insertion genes | Function (animal model) | References |
|---|---|---|---|---|
| HB-98 strain | Porcine | Provided partial protection against the virulent PPV and PRV challenges (mice) | Zheng | |
| Completely protected pigs against maternal PRV infection and significantly reduced the death rate (1/28) after PPV challenge compared with the control (7/31) (pig) | Chen | |||
| HB-98 strain | Porcine | Protected mice against PRV variants infection and significantly reduced the amount of PCV2 viremia (mice) | Zheng | |
| Between | Provided 100% and 80% protection against PRV and JEV infection, respectively (mice) | Qian | ||
| Between | Provided complete protection against maternal PRV and CSFV infection (pig) | Wang YM | ||
| Lei JL | ||||
| Between | Provided complete protection against maternal PRV and CSFV infection without MDAs (pig) | Tong W | ||
| Between | Only protected pigs against PRV infection (pig) | Abid | ||
| SiRNA targeting to the | Safe to pigs and efficiently inhibited HP-PRRSV replication | Cao | ||
| Between | Induced good humoral and cell-mediated immune response in mice (mice) | Yao | ||
| HB-98 strain | Induced partial protection against a lethal challenge with Toxoplasma gondii strain (mice) | Nie | ||
| Between | Significantly increased the survival rate (3/5) after FMDV challenge compared with the control (0/5) (pig) | Zhang |
PPV: porcine parvovirus; PCV2: porcine circovirus type 2; JEV: Japanese encephalitis virus; CSFV: classical swine fever virus; HP-PRRSV: high pathogenic porcine reproductive and respiratory syndrome virus.
Different types of compounds with anti-PRV infection activity.
| Source | Extracts | Mechanism | IC50 | CC50 | PRV strain | MOI | References | ||
|---|---|---|---|---|---|---|---|---|---|
| Resveratrol | Ethanol | Inhibition of viral replication; Inhibition of IKB kinase activation | > 262.87 μmol/L | 17.17 ± 0.35 μmol/L | √ | √ | Rong A | 0.01 | Chen |
| Germacrone | Dimethyl sulfoxide | Inhibition of viral replication | 233.5 μmol/L for Vero, 184.1 μmol/L for PK15 | 54.51 μmol/L for Vero, 88.78 mol/L for PK15 | √ | × | PRV variant Bartha K61 vaccine | 0.1–10 | He |
| Isatis indigotica (leaf) | Ethanol | Inhibition of viral replication | 226 μg/mL | 11 μg/mL | √ | × | TNL | 100 pfu/well | Hsuan |
| Radix isatidis | Ethanol and water | Inhibition of viral replication; Killing virus directly | Not mentioned | Not mentioned | √ | × | MinA | 100 TCID50 | Tong C |
| Marine Bacillus S-12–86 lysozyme | Water | Inhibition of viral replication | 100 μg/mL | 0.46 μg/mL | √ | × | Attenuated | Not mentioned | Zhu |
| Diammonium glycyrrhizin | Not mentioned | Killing virus directly | 1.25 mg/mL | Not mentioned | √ | √ | Bartha K61 vaccine | 104 pfu/mL | Sui |
| Vanadium-substituted Heteropolytungstate | DMEM | Killing virus directly | 400 μg/mL | 5 μg/mL | √ | × | Bartha | 200 TCID50/mL | Liu |
| Graphene Oxide | DMEM | Killing virus directly | Not mentioned | Not mentioned | √ | × | HNX variant | 0.01 | Ye S |
| Ivermectin | Dimethyl sulfoxide | Blocking the nuclear translocation of viral DNA polymerase UL42 | Not mentioned | Not mentioned | √ | √ | Not mentioned | 0.01 | Lv |
| Phosphonoformate sodium | Not mentioned | Inhibition of viral DNA polymerase | 480 μg/mL | Nearly 60 μg/mL | √ | × | Kaplan | 2 | Ren |